Voyager Therapeutics (VYGR) Total Current Liabilities (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Total Current Liabilities data on file, last reported at $17.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 56.6% year-over-year to $17.5 million; the trailing twelve-month figure through Mar 2026 stood at $17.5 million (down 56.6% YoY), and the FY2025 full-year result was $26.5 million, down 46.69% from the prior year.
• Total Current Liabilities fell to $17.5 million in Q1 2026, from $26.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $101.7 million in Q1 2022 to a low of $17.5 million in Q1 2026.
• A 5-year average of $53.3 million and a median of $45.4 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 310.8% in 2022 and tumbled 80.39% in 2023, its largest moves.
• Tracing VYGR's Total Current Liabilities over 5 years: stood at $72.6 million in 2022, then retreated by 11.13% to $64.5 million in 2023, then fell by 22.82% to $49.8 million in 2024, then plunged by 46.69% to $26.5 million in 2025, then sank by 34.24% to $17.5 million in 2026.
• Business Quant data shows VYGR's Total Current Liabilities at $17.5 million in Q1 2026, $26.5 million in Q4 2025, and $35.5 million in Q3 2025.